Evidence map›Paper›PMID 27541593›Full record

ArticleHuman vaccines & immunotherapeutics2016

Preclinical immunogenicity and safety of a Group A streptococcal M protein-based vaccine candidate.

Michael R Batzloff, Anne Fane, Davina Gorton, Manisha Pandey, Tania Rivera-Hernandez, Ainslie Calcutt, Grace Yeung, Jon Hartas, Linda Johnson, Catherine M Rush and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Michael R Batzloffa Institute for Glycomics, Gold Coast Campus, Griffith University , Queensland , Australia.
Anne Faneb Infectious Diseases and Immunopathogenesis Research Group , Australian Institute of Tropical Health and Medicine, James Cook University , Queensland , Australia.
Davina Gortonb Infectious Diseases and Immunopathogenesis Research Group , Australian Institute of Tropical Health and Medicine, James Cook University , Queensland , Australia.
Manisha Pandeya Institute for Glycomics, Gold Coast Campus, Griffith University , Queensland , Australia.
Tania Rivera-Hernandeza Institute for Glycomics, Gold Coast Campus, Griffith University , Queensland , Australia.
Ainslie Calcutta Institute for Glycomics, Gold Coast Campus, Griffith University , Queensland , Australia.
Grace Yeunga Institute for Glycomics, Gold Coast Campus, Griffith University , Queensland , Australia.
Jon Hartasa Institute for Glycomics, Gold Coast Campus, Griffith University , Queensland , Australia.
Linda Johnsonb Infectious Diseases and Immunopathogenesis Research Group , Australian Institute of Tropical Health and Medicine, James Cook University , Queensland , Australia.
Catherine M Rushb Infectious Diseases and Immunopathogenesis Research Group , Australian Institute of Tropical Health and Medicine, James Cook University , Queensland , Australia.
James McCarthyc QIMR Berghofer Medical Research Institute , Herston , Queensland , Australia.
Natkunam Ketheesanb Infectious Diseases and Immunopathogenesis Research Group , Australian Institute of Tropical Health and Medicine, James Cook University , Queensland , Australia.
Michael F Gooda Institute for Glycomics, Gold Coast Campus, Griffith University , Queensland , Australia.

Funding

Global GAS Vaccine Based On The M-ProteinU01AI060579 · NIAID · QUEENSLAND INSTITUTE OF MEDICAL RESEARCH · PI GOOD, MICHAEL F · 2004 to 2008
$2.8M
NIAID NIH HHS U01 AI060579
6 · The paper itself

Abstract

Streptococcus pyogenes (group A streptococcus, GAS) causes a wide range of clinical manifestations ranging from mild self-limiting pyoderma to invasive diseases such as sepsis. Also of concern are the post-infectious immune-mediated diseases including rheumatic heart disease. The development of a vaccine against GAS would have a large health impact on populations at risk of these diseases. However, there is a lack of suitable models for the safety evaluation of vaccines with respect to post-infectious complications. We have utilized the Lewis Rat model for cardiac valvulitis to evaluate the safety of the J8-DT vaccine formulation in parallel with a rabbit toxicology study. These studies demonstrated that the vaccine did not induce abnormal pathology. We also show that in mice the vaccine is highly immunogenic but that 3 doses are required to induce protection from a GAS skin challenge even though 2 doses are sufficient to induce a high antibody titer.

Indexed as

AnimalsAntibodies, BacterialAntigens, BacterialBacterial Outer Membrane ProteinsCarrier ProteinsDisease Models, AnimalDrug Evaluation, PreclinicalFemaleMaleMiceRabbitsRats, Inbred LewStreptococcal InfectionsStreptococcal VaccinesStreptococcus pyogenesTreatment OutcomeAntibodies, BacterialAntigens, BacterialBacterial Outer Membrane ProteinsCarrier Proteinsstreptococcal M proteinStreptococcal VaccinesVaccines, SubunitM-proteinpeptiderheumatic feverrheumatic heart diseasestreptococcus pyogenesvaccine

Identifiers

PMID27541593
PMCPMC5215552

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.